(Q84566153)

English

Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial

scientific article published on 20 July 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

prostatic hypertrophy

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

Claus G Roehrborn

1

object named as

Claus G Roehrborn

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

J Curtis Nickel

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Gerald L Andriole

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

R Paul Gagnier

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Libby Black

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Timothy H Wilson

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Roger S Rittmaster

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

publication date

20 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

78

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

641-646

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

The progression of benign prostatic hyperplasia: examining the evidence and determining the risk

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

Benign prostatic hyperplasia: a progressive disease of aging men.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

The long-term outcome of medical therapy for BPH.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

Effect of dutasteride on the risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

The natural history of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

The so-called "placebo effect" in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

Identifiers

10.1016/J.UROLOGY.2011.03.063

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84566153&oldid=1978619437"